Cargando…
A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
In the past, there was no second-line chemotherapeutic agent suitable for use when urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several new treatment options, such as immune checkpoint inhibitors or targeted therapy have shifted the treatment paradigm regarding s...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Urological Association
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262489/ https://www.ncbi.nlm.nih.gov/pubmed/35670004 http://dx.doi.org/10.4111/icu.20220061 |